V Akbari1, F Hendijani1, A Feizi2, J Varshosaz3, Z Fakhari4, S Morshedi4, S A Mostafavi5. 1. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Isfahan University of Medical Sciences, 81745, Isfahan, Iran. 2. Department of Biostatistics and Epidemiology, Faculty of Public Health, Isfahan University of Medical Sciences, 81745, Isfahan, Iran. 3. Department of Pharmaceutics, Faculty of Pharmacy, Isfahan University of Medical Sciences, 81745, Isfahan, Iran. 4. Student Research Center, Faculty of Pharmacy, Isfahan University of Medical Sciences, 81745, Isfahan, Iran. 5. Department of Pharmaceutics, Faculty of Pharmacy, Isfahan University of Medical Sciences, 81745, Isfahan, Iran. mostafavi@pharm.mui.ac.ir.
Abstract
INTRODUCTION: A systematic review and meta-analysis of interventional studies was conducted to compare the efficacy and safety of oral insulin versus subcutaneous (SC) insulin in diabetic patients. METHODS: Medline, Scopus, ISI Web of Knowledge and Cochrane Central Register of Controlled Trials were searched. Two independent reviewers evaluated studies for eligibility and quality and extracted the data. The primary outcomes were fasting blood glucose (FBG), 1h and 2h postprandial blood glucose, HbA1c, AUC of insulin, C max and T max of insulin, and T max of glucose infusion rate. Secondary outcomes were adverse events. RESULTS: Eleven studies (n = 373) met the inclusion criteria. Meta-analyses showed that there is no significant difference between oral and SC insulin in controlling HbA1c, FBG, 1 and 2 h postprandial blood glucose and producing C max of insulin (P > 0.05); however oral insulin had faster action as indicated by the shorter T max, compared to SC insulin (P < 0.05). The most included studies were varied in their methodological quality. CONCLUSION: This systematic review and meta-analysis showed that oral insulin is comparable to SC insulin with regard to glycemic efficacy and safety. However, is necessary to conduct additional studies in which oral insulin administered to large number of patients for long enough periods of time.
INTRODUCTION: A systematic review and meta-analysis of interventional studies was conducted to compare the efficacy and safety of oral insulin versus subcutaneous (SC) insulin in diabeticpatients. METHODS: Medline, Scopus, ISI Web of Knowledge and Cochrane Central Register of Controlled Trials were searched. Two independent reviewers evaluated studies for eligibility and quality and extracted the data. The primary outcomes were fasting blood glucose (FBG), 1h and 2h postprandial blood glucose, HbA1c, AUC of insulin, C max and T max of insulin, and T max of glucose infusion rate. Secondary outcomes were adverse events. RESULTS: Eleven studies (n = 373) met the inclusion criteria. Meta-analyses showed that there is no significant difference between oral and SC insulin in controlling HbA1c, FBG, 1 and 2 h postprandial blood glucose and producing C max of insulin (P > 0.05); however oral insulin had faster action as indicated by the shorter T max, compared to SC insulin (P < 0.05). The most included studies were varied in their methodological quality. CONCLUSION: This systematic review and meta-analysis showed that oral insulin is comparable to SC insulin with regard to glycemic efficacy and safety. However, is necessary to conduct additional studies in which oral insulin administered to large number of patients for long enough periods of time.
Authors: Shosuke Satake; Mary Courtney Moore; Kayano Igawa; Margaret Converse; Benjamin Farmer; Doss W Neal; Alan D Cherrington Journal: Diabetes Date: 2002-06 Impact factor: 9.461
Authors: L Chaillous; H Lefèvre; C Thivolet; C Boitard; N Lahlou; C Atlan-Gepner; B Bouhanick; A Mogenet; M Nicolino; J C Carel; P Lecomte; R Maréchaud; P Bougnères; B Charbonnel; P Saï Journal: Lancet Date: 2000-08-12 Impact factor: 79.321